AbbVie Inc . (NYSE:ABBV), a Delaware-incorporated pharmaceutical company with a market capitalization of $339 billion and annual revenue exceeding $56 billion, has entered into a $3 billion unsecured ...

We recently compiled a list of the Jim Cramer Shed Light on These 8 Stocks Recently. In this article, we are going to take a ...

AbbVie (NYSE:ABBV – Get Free Report) had its price target lifted by equities researchers at UBS Group from $181.00 to $190.00 in a note issued to investors on Monday,Benzinga reports. The brokerage ...

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $183.9 which represents a slight increase of $8.25 or 4.70% from the prior close of $175.65. The stock opened at $187.3 and touched a low ...

AbbVie Inc. (NYSE:ABBV) discovers, develops, manufactures and sells pharmaceuticals worldwide. It is set to report the Q4 ...

AbbVie Inc.’s stock rose 5% early Friday to lead S&P 500 gainers premarket, after the drug company beat fourth-quarter ...

AbbVie (NYSE:ABBV – Get Free Report) had its target price raised by equities research analysts at Wells Fargo & Company from $195.00 to $210.00 in a note issued to investors on Monday,Benzinga reports ...

AbbVie Inc. (NYSE:ABBV) shares are trading higher on Friday. The company reported fourth-quarter adjusted earnings per share ...

AbbVie reported strong Q4 results, driven by Skyrizi, Rinvoq, neuroscience products, and eye care. Click here to find out why ...

Jeffrey Stewart; Executive Vice President, Chief Commercial Officer; AbbVie Inc Carrie Strom; Senior Vice President, AbbVie and President, Global Allergan Aesthetics; AbbVie Inc Roopal Thakkar ...

Learn more about whether AbbVie Inc. or Genmab A/S is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

AbbVie Inc. closed 14.67% below its 52-week high of $207.32, which the company achieved on October 31st.